GI Longevity

GI Longevity is a clinical-stage biotechnology company focused on the gut-brain axis and its role in neurodegenerative and metabolic diseases. The company's lead candidate, ENT-01, is a synthetic small molecule derived from squalamine that displaces alpha-synuclein aggregates from the enteric nervous system, aiming to treat Parkinson's disease and related conditions. By targeting the gut, the company seeks to address systemic disease progression before it reaches the central nervous system. Additionally, GI Longevity is developing ENT-03, a compound targeting PTP1B for the treatment of metabolic disorders like obesity and type 2 diabetes. The firm is led by pioneers in the field of squalamine research and neuro-gastroenterology. Its approach represents a novel paradigm in treating chronic diseases by intervening at the level of the gastrointestinal tract.